H
Harlan M. Krumholz
Researcher at Yale University
Publications - 1966
Citations - 177853
Harlan M. Krumholz is an academic researcher from Yale University. The author has contributed to research in topics: Myocardial infarction & Population. The author has an hindex of 85, co-authored 1826 publications receiving 159216 citations. Previous affiliations of Harlan M. Krumholz include Veterans Health Administration & Robert Wood Johnson Foundation.
Papers
More filters
Journal ArticleDOI
ACC/AHA 2008 Statement on Performance Measurement and Reperfusion Therapy
Frederick A. Masoudi,Robert O. Bonow,Ralph G. Brindis,Christopher P. Cannon,Jo DeBuhr,Susan Fitzgerald,Paul A. Heidenreich,Kalon K.L. Ho,Harlan M. Krumholz,Chris Leber,David J. Magid,David S. Nilasena,John S. Rumsfeld,Sidney C. Smith,Thomas P. Wharton +14 more
TL;DR: This document is an official document of the American College of Cardiology (ACC)/AHA Task Force on Performance Measures, which formed a work group to address the challenges of performance measurement and reperfusion therapy.
Journal ArticleDOI
Mental disorders, quality of care, and outcomes among older patients hospitalized with heart failure: an analysis of the national heart failure project.
TL;DR: Quality of care measures, including left ventricular ejection fraction (LVEF) assessment, prescription of an angiotensin-converting enzyme (ACE) inhibitor at discharge among patients without treatment contraindications, and 1-year readmission and1-year mortality are evaluated.
Journal ArticleDOI
Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients?
TL;DR: The limited performance of the simple risk index highlights the limitations of applying prognostic models derived in RCT populations to the general population of patients 65 years and older.
Journal ArticleDOI
Survival after Acute Myocardial Infarction (SAMI) study: The design and implementation of a positive deviance study
TL;DR: The SAMI study is presented, a national positive deviance study to discover hospital strategies associated with lower 30-day hospital risk-standardized mortality rates (RSMRs) and generates and test hypotheses about factors most strongly associated with exemplary performance based on practices currently in use.
Journal ArticleDOI
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Behnood Bikdeli,Azita Hajhossein Talasaz,Farid Rashidi,Babak Sharif-Kashani,Mohsen Farrokhpour,Hooman Bakhshandeh,S H Sezavar,Ali Dabbagh,Mohammad Taghi Beigmohammadi,Pooya Payandemehr,Mahdi Yadollahzadeh,Taghi Riahi,Hossein Khalili,Sepehr Jamalkhani,Parisa Rezaeifar,Atefeh Abedini,Somayeh Lookzadeh,Shaghayegh Shahmirzaei,Ouria Tahamtan,Samira Matin,Ahmad Amin,Seyed Ehsan Parhizgar,David Jiménez,Aakriti Gupta,Mahesh V. Madhavan,Sahil A. Parikh,Manuel Monreal,Naser Hadavand,Alireza Hajighasemi,Majid Maleki,Saeed Sadeghian,Bahram Mohebbi,Gregory Piazza,Ajay J. Kirtane,Gregory Y.H. Lip,Harlan M. Krumholz,Samuel Z. Goldhaber,Parham Sadeghipour +37 more
TL;DR: INSPIRATION and INSPIRATON-S studies will help address clinically-relevant questions for antithrombotic therapy and thromboinflammatory therapy in critically-ill patients with COVID-19 and test two independent hypotheses within a randomized control trial with 2 × 2 factorial design.